Skip to main content
WeightCited

Glutamine Obesity

C エビデンス 小規模研究からのエビデンスは限られていますが、いくつかの肯定的なシグナルがあります。

RCT (n=66) found 30 g/day reduced weight and waist circumference comparably to isonitrogenous protein control. Systematic review of 7 trials found improved inflammatory markers and gut barrier function in obese patients. Evidence is preliminary but growing, with benefits potentially mediated through the gut-metabolic axis.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'ingredient\u003Dglutamine\u0026condition\u003Dobesity'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

結論

RCT (n=66) found 30 g/day reduced weight and waist circumference comparably to isonitrogenous protein control. Systematic review of 7 trials found improved inflammatory markers and gut barrier function in obese patients. Evidence is preliminary but growing, with benefits potentially mediated through the gut-metabolic axis.

Key Study Findings

Other
[Nutrition in the prevention and healing of chronic wounds. Importance in improving the diabetic foot].
Dose: None vs: None Outcome: None 効果: None None

対象集団: chronic wounds and have been linked to delayed wound healing and dehiscence

Review
Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans.
Dose: None vs: None Outcome: None 効果: None None

対象集団: Humans (general)

Review
The Na+/Cl--Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB0,+): Emerging Roles in Multiple Diseases and Therapeutic …
Dose: None vs: None Outcome: None 効果: None None

対象集団: Cancer patients (SLC6A14 transporter review)

Key Statistics

7

研究数

300

参加者数

Positive

C

グレード

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
5-10 g/day
guthealth:
10-20 g/day
exerciserecovery:
5-10 g pre/post workout

上限量: 40 g/day (well-tolerated in clinical trials)

研究で検討された用量

用量 期間 効果 N
None -- Positive --
None -- Mixed --
None -- Mixed --

推奨摂取タイミング: Between meals or pre/post-exercise; may add to protein shakes

Safety & Side Effects

報告されている副作用

  • Bloating
  • GI discomfort
  • Constipation

既知の相互作用

  • Lactulose (may reduce effectiveness)
  • Anticonvulsants (may reduce effectiveness)

耐容上限摂取量: 40 g/day (well-tolerated in clinical trials)

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Glutamine help with Obesity?
Based on 7 studies with 300 participants, there is limited but promising evidence that Glutamine may support Obesity management. Our evidence grade is C (Some Evidence).
How much Glutamine should I take for Obesity?
Studies have used various dosages. A commonly studied range is 5-10 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Glutamine?
Reported side effects may include Bloating, GI discomfort, Constipation. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Glutamine and Obesity?
We rate the evidence as Grade C (Some Evidence). This rating is based on 7 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.

References

  1. [1] Guoyao Wu et al.. Adv Exp Med Biol. 2021. Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans. doi:10.1007/978-3-030-74180-8_10 PubMed
  2. [2] Rosa María Martínez García et al.. Nutr Hosp. 2021. [Nutrition in the prevention and healing of chronic wounds. Importance in improving the diabetic foot]. doi:10.20960/nh.03800 PubMed
  3. [3] Mohd Omar F Sikder et al.. AAPS J. 2017. The Na+/Cl--Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB0,+): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis. doi:10.1208/s12248-017-0164-7 PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。